Skip to main content
Equibles

UBS Group AG

Position in BNTX — BioNTech SE

CIK 1610520 ZURICH, V8
Back to BNTX Full portfolio

Position in BNTX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$24,412,690
+$3,033,675 QoQ
Shares Held
262,361
+9.1% QoQ
Ownership
0.104%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#39
of 282 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 85% Shared 0% None 15%

Common Shares in BNTX Over Time

Shares Held

Position Value (USD)

Derivatives in BNTX

reported options exposure · as of Jun 30, 2026
CallValue
$46,525
CallShares
500
PutValue
$780,689
PutShares
8,390

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,751,270,180 across 562 Biotechnology names. BNTX ranks #66 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in BNTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $24,412,690 262,361
2026-06-30 $780,689 8,390
2026-06-30 $46,525 500
2026-03-31 $621,271 6,990
2026-03-31 $604,384 6,800
2026-03-31 $21,379,015 240,538
2025-12-31 $22,997,749 241,573
2025-12-31 $4,817,120 50,600
2025-12-31 $10,719,520 112,600
2025-09-30 $11,104,612 112,600
2025-09-30 $4,990,172 50,600
2025-09-30 $59,905,731 607,440
2025-06-30 $27,499,922 258,288
2025-06-30 $5,387,382 50,600
2025-06-30 $15,182,622 142,600
2025-03-31 $5,754,992 63,200
2025-03-31 $44,977,354 493,931
2025-03-31 $11,682,998 128,300
2024-12-31 $60,285,587 529,053
2024-12-31 $19,553,820 171,600
2024-12-31 $12,181,255 106,900
2024-09-30 $14,606,451 122,981
2024-09-30 $19,870,221 167,300
2024-09-30 $10,867,455 91,500
2024-06-30 $5,697,524 70,900
2024-06-30 $4,347,476 54,100
2024-06-30 $13,303,113 165,544
2024-03-31 $8,498,807 92,128
2024-03-31 $48,735,675 528,300
2024-03-31 $3,533,175 38,300
2023-12-31 $12,008,128 113,778
2023-12-31 $14,564,520 138,000
2023-12-31 $5,287,554 50,100
2023-09-30 $13,693,202 126,042
2023-09-30 $3,943,632 36,300
2023-09-30 $13,145,440 121,000
2023-06-30 $11,113,442 102,969
2023-03-31 $4,359,950 35,000
2023-03-31 $3,114,250 25,000
2023-03-31 $10,915,320 87,624
2022-12-31 $3,004,400 20,000
2022-12-31 $6,174,042 41,100
2022-12-31 $19,031,670 126,692
2022-09-30 $4,046,400 30,000
2022-09-30 $19,051,663 141,249
2022-06-30 $26,312,123 176,473
2022-03-31 $699,296 4,100
2022-03-31 $9,193,184 53,900
2022-03-31 $29,171,558 171,034
2021-12-31 $25,780,000 100,000

Report a Problem

Category
Description
Email (optional, for follow-up)